Eli Lilly's Foundayo Stalls at 19,550 Prescriptions, Lagging Oral Wegovy's 105,000
Updated
Updated · The Motley Fool · Jul 14
Eli Lilly's Foundayo Stalls at 19,550 Prescriptions, Lagging Oral Wegovy's 105,000
1 articles · Updated · The Motley Fool · Jul 14
Summary
Foundayo's weekly prescription growth has been flat for five straight weeks, reaching 19,550 in its 13th week after launch, according to Jefferies-cited IQVIA data.
That trails Novo Nordisk's oral Wegovy pill, which topped 105,000 prescriptions at the same post-launch point, suggesting a much stronger early rollout for Novo's oral obesity drug.
Coverage and familiarity may explain part of the gap: oral Wegovy uses the same semaglutide as Novo's injectables, while Foundayo is a new GLP-1 product and gained major pharmacy-benefit-manager coverage later.
Lilly still has potential advantages in the oral market because Foundayo lacks the food and beverage restrictions tied to oral Wegovy, even as Lilly already holds about 60% of the U.S. GLP-1 market.